Which actors are involved in the emergent psychedelic medicine space? We created this page to demonstrate some of those involved, from research institutes through to government bodies. This page is updated regularly; feel free to get in touch with suggestions.
Johns Hopkins University: Center for Psychedelic and Consciousness Research
In September 2019, Johns Hopkins University launched their Center for Psychedelic and Consciousness Research, propelled by $17 million of private funding.
American entrepreneur Tim Ferriss was among the donors.
Johns Hopkins University School of Medicine
As well as having a dedicated Center for Psychedelic and Consciousness Research, in 2018 Johns Hopkins’ School of Medicine made a public statement urging the U.S. Government to reschedule psilocybin.
Imperial College London: Center for Psychedelic Research
In April 2019, Imperial College London launched the world’s first formal centre for psychedelic research.
As with the Johns Hopkins Center for Psychedelic and Consciousness Research, Tim Ferriss was a leading donor.
Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London
In the United Kingdom, Compass Pathways has worked with the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London to successfully conduct a double-blind, placebo-controlled study with nearly ninety participants between 18-65 years of age. The study found that psilocybin was well-tolerated by the healthy adult volunteers.
We have selected a few examples of media interest in psychedelic medicines.
Bloomberg: 2018 Alternative Investment Guide
Bloomberg included shroom stocks in their 2018 alternative investments guide, alongside art and Ferraris. The title of the article leads with psychedelics: Psychedelics, Ferraris and Art: An Alternative Investment Guide.
CBS 60 Minutes feature
In October 2019, CBS aired an episode of their popular 60 minutes series that focussed on the potential for psychedelics to help people with addiction and anxiety.
Included in the production were interviewees from the Johns Hopkins Center for Psychedelic and Consciousness Research.
You can watch the full episode here.
U.S. Food and Drug Administration (FDA)
The FDA has already awarded Breakthrough Therapy Designation to a number of psychedelic medicines, including psilocybin-based formulas.
The FDA has also approved drugs that employ psychedelic substances, such as GW Pharmaceuticals’ Epidiolex, a cannabis-based epilepsy medicine.
U.S. Drug Enforcement Administration (DEA)
While psilocybin and other psychedelic substances remain Schedule I drugs, the DEA has shown some willingness to reschedule drugs where they have approved medicinal uses. For example, in 2018 the DEA rescheduled Epidiolex, a cannabis-based epilepsy medicine developed by GW Pharmaceuticals, following its FDA approval.
UK National Health Service (NHS)
A number of NHS trusts are working with Compass Pathways to provide test sites for their clinical trials.
Billionaire investor Mike Novogratz has been a vocal proponent of the emergent psychedelic medicine space, claiming:
“It just feels like a cultural shift going on […] it’s been around for thousands of years; people kind of know its side effects”
Novogratz is an investor in Compass Pathways.
The PayPal co-founder and Silicon Valley billionaire has invested in Compass Pathways via his venture capital firm, Thiel Capital.
Psychedelic Medicine Stocks & Companies
View our live page of stocks and companies active in the pyschedelic medicine space.